These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34810046)

  • 1. The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study.
    Chargi N; Molenaar-Kuijsten L; Huiskamp LFJ; Devriese LA; de Bree R; Huitema ADR
    Eur J Cancer; 2022 Jan; 160():92-99. PubMed ID: 34810046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer.
    Chargi N; Bashiri F; Wendrich AW; Smid EJ; de Jong PA; Huitema ADR; Devriese LA; de Bree R
    Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3685-3694. PubMed ID: 35038029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin.
    Bril SI; Al-Mamgani A; Chargi N; Remeijer P; Devriese LA; de Boer JP; de Bree R
    Head Neck; 2022 Jan; 44(1):189-200. PubMed ID: 34713519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer.
    Wendrich AW; Swartz JE; Bril SI; Wegner I; de Graeff A; Smid EJ; de Bree R; Pothen AJ
    Oral Oncol; 2017 Aug; 71():26-33. PubMed ID: 28688687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol.
    Schaeffers AWMA; Devriese LA; van Gils CH; Dankbaar JW; Voortman J; de Boer JP; Slingerland M; Hendriks MP; Smid EJ; Frederix GWJ; de Bree R
    PLoS One; 2023; 18(11):e0294147. PubMed ID: 38011186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy.
    Huiskamp LFJ; Chargi N; Devriese LA; de Jong PA; de Bree R
    Eur Arch Otorhinolaryngol; 2020 Oct; 277(10):2847-2858. PubMed ID: 32335709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer.
    Jung AR; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2019 Aug; 95():95-99. PubMed ID: 31345401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.
    de Jong C; Chargi N; Herder GJM; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; de Jong PA; Devriese LA; Huitema ADR; Egberts TCG; de Bree R; Deneer VHM
    J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1554-1564. PubMed ID: 35301821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of relative cisplatin dose to skeletal muscle mass on adverse events in patients with head and neck cancer undergoing chemoradiotherapy.
    Suzuki S; Yokota T; Notsu A; Hamauchi S; Onozawa Y; Fushiki K; Oshima K; Kawakami T; Tsushima T; Yasui H; Ogawa H; Onoe T; Kawatani K; Yamazaki K
    Oncologist; 2024 Jul; ():. PubMed ID: 38979778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy.
    Chargi N; Wegner I; Markazi N; Smid E; de Jong P; Devriese L; de Bree R
    J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33919607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy.
    Becker JN; Hermann R; Wichmann J; Sonnhoff M; Christiansen H; Bruns F
    PLoS One; 2023; 18(2):e0282015. PubMed ID: 36802403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.
    Antoun S; Bayar MA; Dyevre V; Lanoy E; Smolenschi C; Ducreux M
    BMC Cancer; 2019 Aug; 19(1):847. PubMed ID: 31462288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma.
    Nishikawa D; Hanai N; Suzuki H; Koide Y; Beppu S; Hasegawa Y
    ORL J Otorhinolaryngol Relat Spec; 2018; 80(1):1-9. PubMed ID: 29393251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal muscle mass at C3 may not be a strong predictor for skeletal muscle mass at L3 in sarcopenic patients with head and neck cancer.
    Yoon JK; Jang JY; An YS; Lee SJ
    PLoS One; 2021; 16(7):e0254844. PubMed ID: 34280248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives.
    Erul E; Guven DC; Onur MR; Yazici G; Aksoy S
    Eur Arch Otorhinolaryngol; 2023 Aug; 280(8):3541-3556. PubMed ID: 37188907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
    Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.
    Molenaar-Kuijsten L; Jacobs BAW; Kurk SA; May AM; Dorlo TPC; Beijnen JH; Steeghs N; Huitema ADR
    Cancer Med; 2021 Jul; 10(14):4781-4789. PubMed ID: 34121365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial.
    Rampino M; Ricardi U; Munoz F; Reali A; Barone C; Musu AR; Balcet V; Franco P; Grillo R; Bustreo S; Pecorari G; Cavalot A; Garzino Demo P; Ciuffreda L; Ragona R; Schena M
    Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):134-40. PubMed ID: 21030225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment.
    Duran G; Aguín S; Cruz R; Barros F; Giráldez JM; Bernárdez B; López-López R; Carracedo Á; Lamas MJ
    Head Neck; 2019 Aug; 41(8):2704-2715. PubMed ID: 30973677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study.
    Visacri MB; Pincinato EC; Ferrari GB; Quintanilha JCF; Mazzola PG; Lima CSP; Moriel P
    Daru; 2017 Apr; 25(1):12. PubMed ID: 28438219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.